undamentalytics Newsletter
Sign in

Acadia Pharmaceuticals Inc income statement

In fiscal 2025, Acadia Pharmaceuticals Inc reported revenue of $1.07bn, up 11.9% on the year before, operating income of $105m (a 9.8% margin) and net income of $391m, or $2.30 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue64225100171252243394424845177269581,0721,139
Cost of revenue————————91211101910428289101
Gross profit———————141162113284324735076858769831,038
Research and development4221171927617499149187240319239362352303329331
Selling, general and administrative—————3388186255266326389396369407488549620
General and administrative1068713—————————————
Operating income−4515−23−21−38−93−165−273−292−247−247−287−170−224−7323110586
Income before tax————−38−92−164−270−288−244−234−281−168−213−51258139121
Income tax—00000011111031032−252−259
Net income−4515−23−21−38−92−164−271−289−245−235−282−168−216−61226391380
Diluted EPS−$1.20$0.39−$0.44−$0.38−$0.44−$0.95−$1.63−$2.34−$2.36−$1.94−$1.60−$1.79−$1.05−$1.34−$0.37$1.36$2.30$2.21
Diluted shares (average)37m39m52m55m86m97m101m116m123m127m147m157m160m162m164m166m170m172m
EBITDA−4416−23−21−38−93−164−272−291−246−245−285−168−222−7223210688

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ACAD vs PTCTACAD vs LKFTACAD vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Acadia Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Acadia Pharmaceuticals Inc.